"Was the Amivantamab news really that surprising? Normally a move into Phase 3 is not going to get everyone that amped up. Was this an undisclosed indication up until now?"
It was not a complete surprise but I think a lot of people were not aware of it because it was undisclosed in halo's presentations for earnings calls. It came up during the earnings call:
"David Risinger
Okay. Thank you. And then just a couple of other questions. So congrats on the amivantamab advance into Phase 3 just so that I understand your disclosure, how is that Janssen program previously disclosed by the company? What was it named or was it just an unidentified J&J program? I just don't know how you handle that disclosure previously.
Helen Torley
So -- and we work with our partners on their preference for how things are disclosed in our SEC filings, like as an example, our P&Q [ph], it was disclosed as amivantamab. In our presentation for earnings calls, it was undisclosed because, again, we work with our partners and their preference, but it's been disclosed since the beginning in our SEC filing documents."
News 
Market Data 
Discover 
AI
